Hyperlipidemia : Part 2. Pharmacologic management

N. Link, M. Tanner
{"title":"Hyperlipidemia : Part 2. Pharmacologic management","authors":"N. Link, M. Tanner","doi":"10.1136/EWJM.175.6.396","DOIUrl":null,"url":null,"abstract":"Pharmacologic therapy for lipid disorders is now dominated by hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). They have been conclusively proved to prevent coronary events and save lives in a wide variety of situations and are acceptably safe. \n \n \n \nAlternatives to statins include resins (eg, cholestyramine), fibric acid derivatives (eg, gemfibrozil), and nicotinic acid (table 1, see p 400). They all have a place in lipid management but should be considered second-line agents. \n \n \n \nTable 1 \n \nAgents for treating hyperlipidemia","PeriodicalId":22925,"journal":{"name":"The Western journal of medicine","volume":"10 1","pages":"396-401"},"PeriodicalIF":0.0000,"publicationDate":"2001-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Western journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/EWJM.175.6.396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmacologic therapy for lipid disorders is now dominated by hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins). They have been conclusively proved to prevent coronary events and save lives in a wide variety of situations and are acceptably safe. Alternatives to statins include resins (eg, cholestyramine), fibric acid derivatives (eg, gemfibrozil), and nicotinic acid (table 1, see p 400). They all have a place in lipid management but should be considered second-line agents. Table 1 Agents for treating hyperlipidemia
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高脂血症:第二部分。药物管理
脂质紊乱的药物治疗现在主要是羟甲基戊二酰辅酶A (HMG-CoA)还原酶抑制剂(他汀类药物)。它们已被明确证明可以预防冠状动脉事件并在各种情况下挽救生命,并且是可接受的安全。他汀类药物的替代品包括树脂(如胆甾胺)、纤维酸衍生物(如吉非罗齐)和烟酸(表1,见第400页)。它们在血脂管理中都有一席之地,但应被视为二线药物。表1治疗高脂血症的药物
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Toxic shock syndrome. Myelodysplastic syndromes. Kawasaki disease. Bioaerosols. Lyme disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1